Milvexian, FXIa Inhibitor, Wins US FDA Fast Track Designation for 3 Indications in Phase 3 Trial Program
Proposed indications for the investigational factor XIa inhibitor are: stroke prevention after acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.